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Background: Women with polycystic ovarian syndrome (PCOS) are known to have elevated circulating Anti-
Müllerian hormone (AMH), which has been found to desensitize ovarian follicles to follicle stimulating hormone
(FSH). The purpose of this study was to investigate the impact of high circulating AMH on ovarian responsiveness
to ovulation induction with gonadotrophins in PCOS women.
Methods: This prospective observational pilot study was conducted in two collaborating Fertility Centres in the UK
and Egypt. The study included 20 consecutive anovulatory women with PCOS who underwent 34 cycles of human
menopausal gonadotrophin (hMG) ovarian stimulation using chronic low-dose step up protocol. Blood samples
were collected for the measurement of serum AMH concentrations in the early follicular (day 2-3) phase in all cycles
of hMG treatment. The serum levels of AMH were compared between cycles with good vs. poor response. The
good response rates and the total dose and duration of hMG treatment were compared between cycles with high
vs. low serum AMH concentrations.
Results: Cycles with poor response (no or delayed ovulation requiring >20 days of hMG treatment) had
significantly (p = .007) higher median{range} serum AMH concentration (6.5{3.2-13.4}ng/ml) compared to that (4.0
{2.2-10.2}ng/ml) of cycles with good response (ovulation within 20 days of hMG treatment). ROC curve showed
AMH to be a useful predictor of poor response to hMG stimulation (AUC, 0.772; P = 0.007). Using a cut-off level of
4.7 ng/ml, AMH had a sensitivity of 100% and specificity of 58% in predicting poor response. The good response
rate was significantly (p < .001) greater in cycles with lower AMH (<4.7 ng/ml) compared to that in those with
AMH > = 4.7 ng/ml (100% vs. 35%, respectively). All cycles with markedly raised serum AMH levels (> 10.2 ng/ml)
were associated with poor response. Cycles with high AMH (> = 4.7 ng/ml) required significantly (p < .001) greater
amounts (median {range}, 1087{450-1650}IU) and longer duration (20 {12-30}days) of hMG stimulation than cycles
with lower AMH (525 {225-900}IU and 8{6-14}days).
Conclusions: PCOS women with markedly raised circulating AMH seem to be resistant to hMG ovulation induction
and may require a higher starting dose.
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Anti-Müllerian hormone (AMH) is a dimeric glycoprotein,
which is secreted exclusively by granulosa cells of primary,
preantral and small antral follicles (4-6 mm). Its secretion
gradually diminishes in the subsequent stages of follicle
development and is practically undetectable in follicles lar-
ger than 8 mm [1]. AMH has been shown to lower the
sensitivity of follicles to circulating follicle stimulating hor-
mone (FSH) [2,3]. Serum AMH concentrations have been
correlated with the number of small follicles and hence
ovarian reserve. In polycystic ovarian syndrome (PCOS)
serum AMH concentration shows a two- to three-fold
increase, which corresponds to the two- to three-fold in-
crease in the number of small (2 – 5 mm) follicles [4,5].
This increase in AMH has been implicated in the patho-
genesis of PCOS. It has been hypothesised that the high
serum AMH levels in PCOS lowers follicular sensitivity to
circulating FSH thus preventing follicle selection resulting
in follicle arrest at the small antral phase with failure of
dominance. AMH also inhibits aromatase activity resulting
in reduction of follicle production of oestradiol (E2) [6].
The resulting low levels of E2 may also contribute to the
failure of follicle selection. It is therefore possible to hy-
pothesise that high serum AMH levels could adversely
affect ovarian responsiveness to gonadotrophin ovulation
induction in women with PCOS.
Serum AMH has recently been widely accepted as an
excellent predictor of ovarian responsiveness to gonado-
trophin treatment in ovulation induction as well as in in-
vitro fertilization (IVF) programmes. In women without
PCOS, serum AMH has been found to correlate positively
with ovarian responsiveness to gonadotrophin stimulation
[7,8]. In women with PCOS, there has been no study on
the predictive value of circulating AMH during gonado-
trophin ovulation induction. Lie Fong and co-workers in-
vestigated the changes in circulating AMH, but not its
predictive value, in PCOS women receiving gonadotrophin
ovulation induction [9]. Although, the title of that paper in-
dicates that AMH is not a useful predictor of ovarian re-
sponse to gonadotrophin treatment in PCOS women, the
study did not investigated that issue at all. Concerning IVF
in PCOS women, data on the influence of circulating
AMH on the outcomes are conflicting. Xi and co-workers
reported negative correlation between serum AMH con-
centrations and fertilization and pregnancy rates in PCOS
women [10]. On the other hand, other studies reported
positive correlation between circulating AMH and IVF
outcomes including pregnancy rates [11] and number and
maturity of retrieved oocytes [12]. Parco and co-workers
reported on the diagnostic, but not the predictive, value of
circulating AMH during IVF [13]. Guzman and co-
workers investigated the predictive usefulness of circulating
AMH in PCOS women undergoing in-vitro maturation
(IVM) treatment [14].In two recent studies involving women with PCOS, we
have found excessive circulating AMH to be associated
with poor ovarian response to laparoscopic ovarian dia-
thermy [15] and clomiphene citrate ovulation induction
[16]. To the best of our knowledge, the impact of circulat-
ing AMH on gonadotrophin ovulation induction in women
with anovulatory PCOS has never previously been investi-
gated. The aim of this study was to assess the predictive
value of circulating AMH in PCOS women undergoing
ovarian stimulation with gonadotrophins.
Methods
This prospective observational pilot study was conducted
at two collaborating sites including the Derby Fertility Unit,
University of Nottingham, UK and the Assisted Concep-
tion Unit, Minia University, Egypt. The study included 20
clomiphene citrate-resistant women with PCOS who re-
ceived 34 cycles of ovulation induction with human meno-
pausal gonadotrophin (hMG) with timed intercourse (TI)
or intrauterine insemination (IUI) between November
2009 and March 2011. The inclusion criteria were: age 18 -
39 years, BMI < = 35 kg/m(2), anovulatory infertility and a
diagnosis of PCOS based on Rotterdam consensus criteria
(two of three criteria: Oligo/anovulation, hyperandrogenae-
mia and sonographic appearance of polycystic ovaries)
[17]. Anovulation was diagnosed when the cycle length
was longer than 6 weeks or when mid-luteal serum proges-
terone concentration was < 10 pmol/L (in women with
shorter cycles). Hyperandrogenism was diagnosed either
clinically (acne/hirsutism) and/or biochemically (testoster-
one > 2.5 nmol/l or free androgen index [FAI] >=5). The
ovary was considered polycystic on ultrasound scan if it
contained >= 12 follicles (2-9 mm in diameter) and/or
measured >10 ml in volume. In addition, all participants
had proven patency of at least one fallopian tube and nor-
mal semen analysis of their male partners according to the
1999 WHO criteria [18]. We excluded women with other
causes of anovulation such as thyroid dysfunction and
hyperprolactinaemia. Patients with marked hyperandro-
genaemia were screened for congenital adrenal hyperplasia
(by measuring serum concentration of 17alpha hydroxyl-
progesterone) and Cushing syndrome (by measuring urin-
ary free cortisol).
Ethical approval
Ethics approval for this study was given by the Derby Ethics
Committee, UK (REC reference: 09/H0401/60, date 07/10/
2009) and by Minia University Hospital Ethics Committee
(Egypt). All participants provided informed written consent.
Outcome measures
The primary study outcome measure was good response
to hMG therapy defined as occurrence of ovulation within
20 days of treatment. The secondary study outcome
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rates and total dose and duration of hMG therapy.
Gonadotrophin therapy
The chronic low-dose step-up hMG stimulation regimen
was utilized in all the cases. One of the investigators (AM)
established and standardized the treatment procedures in
the two collaborating sites. Human menopausal gonado-
trophin (hMG) (Menopur, Ferring, UK) was given starting
on cycle day three in a dose of 75 IU alternate days. The
aim of treatment was to achieve mono-ovulation. Moni-
toring of treatment was achieved by serial transvaginal
ultrasound scanning and serum oestradiol measurements
every other day starting from cycle day nine. Size and
number of follicles and serum oestradiol levels were re-
corded in patients follow up sheets. The dose of hMG was
reviewed around stimulation day 10 and if follicular devel-
opment was unsatisfactory, the dose was increased to 75
IU daily. Further increases of the dose (by adding 75 IU al-
ternate days) were considered at weekly intervals when no
satisfactory response was achieved. If a good response was
not achieved after 28 days, the cycle was cancelled. A new
cycle was commenced with a higher starting dose of
Menopur (75 IU per day). When one follicle reached a size
of > =18 mm a single dose of 10,000 IU human chorionic
gonadotrophin (hCG, Pregnyl, Organon, UK) was given.
In patients scheduled for IUI, this was performed 36 hours
after the hCG injection.
Criteria for cycle cancellation
hMG stimulation cycles were cancelled either due to under
or over response to treatment. Under response was diag-
nosed when there was no follicular growth after 14 days of
stimulation despite increasing the dose of hMG injections
or when follicular growth became arrested after an initial
response. Over response was diagnosed when there were
three or more follicles ≥ 17 mm and/or E2 levels > 5000
nmol/l.
Intrauterine insemination
IUI was performed in 12 patients (22 hMG cycles) using
fresh semen samples by Specialist Nurses (in the Fertility
Unit, Derby, UK) or by the Fertility Clinician (in the
Assisted Conception Unit, Minia Egypt). Insemination was
carried out using the Rocket DUO 23 cm catheter or Bulp
Tip (Embryo Transfer Set) 23 cm in difficult cases (Rocket
Medical, USA). Timed intercourse was advised in three cy-
cles, whilst the remaining nine cycles were cancelled as de-
tailed below.
Luteal phase support
Progesterone support of the luteal phase was com-
menced on the day of IUI with Utrogestan 200 mg vaginal
capsules twice daily (Utrogestan, Ferring, UK) or Prontogest400 mg vaginal pessaries twice daily (Prontogest, Marcyrl,
Egypt).
Diagnosis of pregnancy
Urine pregnancy tests were performed 15 days after IUI.
If the pregnancy test was positive a transvaginal ultra-
sound scan was arranged after two weeks.
Blood collection and AMH assays
A venous blood sample was collected on cycle day 2 of
all cycles of hMG treatment to measure baseline serum
concentrations of AMH. Further blood samples were
collected for the measurement of serum AMH concen-
trations on days 9, 15 and 21 of treatment cycle one.
The samples were immediately transferred to the re-
search laboratory of each centre, centrifuged for 15 mi-
nutes at 2000 X g at 4°C and stored at -80°C for later
analysis for AMH concentrations. Stored samples col-
lected in Minia University were transferred to the re-
search laboratory of the UK site (Derby Medical School)
for analysis. Serum samples were assayed for AMH in
duplicate using enzyme-linked immunosorbent assay kit
(Uscn Life Science Inc., USA), which is a sandwich en-
zyme immunoassay for the in vitro quantitative meas-
urement of AMH in serum, plasma and other biological
fluids. This kit has an intra- and inter-assay coefficient
of variation of less than 10% and less than 12%, respect-
ively. The minimum detectable level of human AMH by
this kit was typically > 0.046 ng/ml with a detection
range of 0.156-10 ng/ml. The assay has high sensitivity
and excellent specificity for detection of human AMH
with no significant cross-reactivity or interference.
Statistical analysis
Data were entered into the Statistical Package for Social
Sciences (SPSS) version 17. Unpaired Mann-Whitney U
test was used to compare serum AMH levels between cy-
cles with good vs. poor response to hMG stimulation (as
defined above). Receiver – operating characteristic (ROC)
curve analysis was used to evaluate the predictive value of
AMH. Chi-square test was used to compare good response
rates between cycles with high vs. low AMH concentra-
tions. The total dose and duration of hMG administration
were compared between cycles with high vs. low serum
AMH concentrations using Mann-Whitney U test. A
P value < 0.05 was considered statistically significant. Logis-
tic regression analysis was used to determine the independ-
ent effect of AMH on ovarian responsiveness to hMG
stimulation after adjusting for other confounders including
age, BMI, testosterone levels, FAI and ovarian volume.
Backward stepwise elimination was used for the multivari-
ate logistic analysis of prediction of patients with good
ovarian responsiveness to hMG stimulation. P > 0.10 was
used as a cut-off level for exclusion of non-significant
Amer et al. Reproductive Biology and Endocrinology 2013, 11:115 Page 4 of 9
http://www.rbej.com/content/11/1/115individual parameters from the prognostic model. The Cox
and Snell square measure of goodness of fit was used to
check for lack of fit of the final model.Results
Patients’ characteristics
Table 1 shows patients’ demographic, clinical and endocrine
characteristics. The baseline median {range} serum concen-
tration of AMH was 5.5 {2.2-13.4} ng/ml, which remained
fairly constant throughout the cycle (day 9, 5.7 {2.1-13.2};
day 15, 5.5 {2.3-13.3} and day 21, 5.6 {2.1-13.1} ng/ml.Outcome of hMG ovarian stimulation
Ovarian responsiveness
Of the 34 cycles of hMG stimulation included in this study,
19 (56%) resulted in a good response (defined as ovulation
within 20 days of hMG stimulation). The remaining 15 cy-
cles were considered poor response (defined as either lack
of ovulation (n = 6) or ovulation after prolonged (>20 days)
hMG stimulation (n = 9). One (5%) of the 19 cycles withTable 1 Demographic, clinical and baseline endocrine feature
hMG ovarian stimulation
Characteristic Overall (n = 20)
Age (years) 29.1 (4.2)
Body mass index (kg/m2) 26.8 (5.3)
Duration of infertility (years) 4.5 (2.7)
Serum LH (IU/L) 9.1 (4.3)
Serum FSH (IU/L) 4.9 (2.4)
Serum LH/FSH ratio 2.3 (1.4)
Serum testosterone (nmol/l) 2.3 (0.7)
Free androgen index 6.4 (2.4)
Ovarian volume (ml) 11.8 (2.7)
Menstrual cycle Regular 2 (10)
Oligomenorrhoea 12 (60)
Amenorrhoea 6 (30)
Hirsutism Yes 9 (45)
No 11 (55)
Acne Yes 11 (55)
No 9 (45)
Infertility Primary 16 (80)
Secondary 4 (20)
Ethnicity Caucasian 8 (40)
Mediterranean 11 (55)
Asian 1 (5)
Results are compared between good vs. poor responders.
Numerical values are presented as mean (SD) and categorical data are given as n (%
poor responders.good response was associated with three follicles > = 17
mm and was therefore cancelled due to over response.
Ovulation and pregnancy rates per cycle
Ovulation occurred in 28 (82%) of the 34 cycles and preg-
nancy was achieved in three (9%) cycles. Nine cycles (26%)
were cancelled either due to lack of response to hMG (n =
8, 23%) or due to over response (three follicles of >17 mm
diameter) (n = 1, 3%).
Ovulation and pregnancy rates per patient
Amongst the 20 PCOS women participating in this study
17 (85%) ovulated and three (15%) conceived.
Cycles with good response vs. cycles with poor response
to hMG stimulation
Base line serum concentrations of AMH, luteinizing hor-
mone (LH), FSH, testosterone, FAI and ovarian volume
were compared between cycles with good and cycles with
poor response (Table 2). AMH was significantly (p = .007)s of 20 anovulatory women with PCOS who underwent
Good responders (n = 12) Poor responders (n = 8)
Mean (SD)
28.3 (4.9) 30.3 (2.6)
27.2 (5.6) 26.3 (5.0)
5.0 (3.0) 3.4 (2.8)
9.5 (3.9) 8.5 (5.0)
5.2 (3.1) 4.5 (0.4)
2.4 (1.7) 1.9 (1.2)
2.3 (0.6) 2.2 (0.7)
6.5 (2.4) 6.2 (2.3)
12.0 (3.0) 12.7 (2.4)
n (%)
2 (17) 0 (0)
8 (66) 4 (50)
2 (17) 4 (50)
6 (50) 5 (63)
6 (50) 3 (37)
6 (50) 3 (37)
6 (50) 5 (63)
10 83 6 75
2 17 2 25
4 33 4 (50)
7 58 4 (50)
1 9 0 (0)
). No statistically significant differences were found between good and
Table 2 Day 2-3 serum hormonal concentrations and ovarian volume in 34 cycles of hMG ovarian stimulation in 20
anovulatory women with PCOS
Cycles with poor response to FSH stimulation* (n = 15) Cycles with good response to FSH stimulation** (n = 19) p
LH (IU/L) 6.7 (1.3-17.4) 8.6 (5.2-18.9) .348
FSH (IU/L) 4.5 (4.0-6.0) 4.5 (1.0-14.1) .650
Testosterone (nmol/l) 2.6 (0.9-3.6) 2.1 (1.6-3.6) .705
FAI 7.0 (2.0-13.0) 6.0 (3.0-13.0) .983
Ovarian volume (ml) 14.1 (8.5-16.7) 10.9 (8.0-16.7) .188
AMH (ng/ml) 6.5 (5.1-13.4) 4.0 (2.2-10.2) .007
The results are compared between cycles with poor response and those with good response. Values are presented as median (range). Mann-Whitney test was
used for comparisons.
*Poor response, is defined as absence of or delayed ovulation (>20 days of hMG stimulation).
**Good response is defined as occurrence of ovulation within 20 days of hMG stimulation.
Figure 1 ROC curve of AMH for predicting good response in 34
cycles of hMG ovarian stimulation and possible cut-off values
with corresponding specificity and sensitivity in predicting
poor response to hMG stimulation.
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with good response.
Responders vs. non-responders
The number of pregnancies (n = 3) and the number of pa-
tients not achieving ovulation (n = 3) were too small to
allow meaningful statistical comparisons. The median
baseline AMH concentrations in pregnant and non-
pregnant women were 3.2 (3.2-13.4) ng/ml and 5.7
(2.2-12.5) ng/ml respectively. The median serum AMH
concentration in women achieving ovulation was 5.1
(2.2-13.4) ng/ml and that of patients who did not ovu-
late was 5.7 (5.3-12.3) ng/ml.
ROC curve
Using a ROC curve, AMH was found to be a useful pre-
dictor of poor response to hMG ovarian stimulation with
an AUC of .772 (p = .007) (Figure 1). Different cut-offs of
AMH levels in predicting response to hMG stimulation
with the corresponding sensitivity and specificity are also
shown (Figure 1). Using a cut-off value of 4.7 ng/ml,
AMH had a sensitivity of 100% and specificity of 58% in
predicting poor response to hMG ovarian stimulation.
Ovarian response in cycles with high vs. low AMH
Using a cut-off AMH value of 4.7 ng/ml (as determined
by the ROC curve), the outcomes of hMG ovarian
stimulation were compared between cycles with high
AMH vs. low AMH levels. Cycles with high AMH levels
had significantly lower rates of good ovarian response
and higher rates of cancellation (Table 3). The results
also showed a trend towards lower ovulation rates in cy-
cles with high AMH levels, but this did not reach statis-
tical significance (Table 3).
Figure 2 illustrates the rates of good response in PCOS
women with low (<4.7 ng/ml), moderately elevated (4.7 –
10.2 ng/ml) and markedly elevated (>10.2 ng/ml) serum
AMH concentrations. The results show 100% good re-
sponse rate in women with AMH <4.7 ng/ml and 100%
poor response rate in patients with AMH> 10.2 ng/ml.AMH and the total dose and duration of hMG stimulation
Spearman's correlation revealed a statistically significant
positive correlation between baseline serum AMH con-
centration and the total dose and duration of hMG ad-
ministration (Figure 2). No significant correlation was
found between AMH and the maximum serum oestradiol
concentration (data not shown).
Total dose and duration of hMG stimulation in cycles with
low v. high AMH
hMG stimulation cycles with high baseline AMH (≥4.7
ng/ml) required significantly greater amounts and longer
duration of hMG stimulation than cycles with lower AMH
(Table 4).
Table 3 Clinical outcomes of hMG ovarian stimulation in cycles with high AMH (> = 4.7 ng/ml) vs. cycles with low AMH
(<4.7 ng/ml)
Outcome AMH < 4.7 ng/ml (11 cycles) AMH > = 4.7 ng/ml (23 cycles) P RR (95% CI)
Good response 11 (100%) 8 (35%) <.001 2.88 (1.64-5.03)
Ovulation 11 (100%) 17 (74%) .075 1.35 (1.06-1.72)
Cancellation 0 (0%) 9* (39%) .01 1.64 (1.18-2.28)
Over response 0 (0%) 1 (4%) .535 1.15 (0.98-1.35)
Pregnancy 2 (18%) 1 (4%) .239 0.21 (0.02-2.50)
Data are presented as n (%). Chi square was used for comparisons.
*Of the 9 cancellations, 8 were due to poor response and 1 was due to over response.
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and clinical characteristics
Spearman’s correlation revealed a strong positive correl-
ation between baseline AMH levels and serum testoster-
one levels, FAI and ovarian volume (Figures 3 and 4). No
significant correlation was found between AMH and pa-
tients’ age, BMI, LH or FSH (data not shown).
Endocrine features and ovarian volume in PCOS women
with high vs. low AMH
PCOS women with high AMH had significantly higher
serum concentration of testosterone, FAI and ovarian
volume as shown on Table 5.
Logistic regression
Logistic regression analysis including AMH, age, BMI,
testosterone, FAI and ovarian volume as independent
predictors of ovarian responsiveness to hMG stimula-
tion, showed AMH to be the most important independ-
ent factor. The final logistic regression model had an R
(2) (Cox and Snell) of 0.558.
Discussion
In this study, we have evaluated the impact of circulating
AMH on the outcome of ovarian stimulation in 20
women with anovulatory PCOS undergoing 34 cycles of
gonadotrophin treatment. To the best of our knowledge,
this is the first study to address this important issue inFigure 2 Good response rates in 34 cycles of hMG ovarian
stimulation in PCOS women with different serum AMH levels.women with PCOS. We found circulating AMH levels
to be negatively correlated with ovarian response to
hMG. Furthermore, we have identified a cut-off level of
serum AMH concentration (4.7 ng/ml), above which the
chances of good ovarian response were markedly re-
duced from 100% (in women with lower AMH) to 35%.
Furthermore, we have demonstrated that PCOS women
with higher levels of AMH require higher doses of hMG
and longer duration of treatment. In addition, we have
shown significantly higher cancellation rates in patients
with higher AMH.
The negative influence of high AMH levels on ovarian
responsiveness to gonadotrophin therapy may reflect the
correlation between rising serum AMH levels and in-
creasing severity of PCOS. It is assumed that severe
PCOS is associated with an increased number of small
antral follicles (the only source of AMH) resulting in ex-
cessive AMH secretion. Another possible explanation is
the negative effect of excessive AMH secretion on the
sensitivity of growing antral follicles to the administered
gonadotrophin preventing folliculogenesis [2,3].
These findings suggest that high circulating AMH is as-
sociated with ovarian resistance to gonadotrophin ovarian
stimulation. However, it is important to note that over re-
sponse to hMG could still occur in women with moder-
ately elevated circulating AMH (4.7 – 10.2 ng/ml). On the
other hand, none of the PCOS patients with markedly
raised circulating AMH achieved a good response to hMG
treatment.
These findings are consistent with our previous studies
on the impact of circulating AMH on the outcome of
laparoscopic ovarian drilling and clomiphene citrateTable 4 comparison of the total dose and duration of hMG
in cycles with high (≥4.7 ng/ml) vs. low AMH (<4.7 ng/ml)
FSH ovarian
stimulation
All cycles AMH ≥ 4.7
ng/ml
(23 cycles)
AMH < 4.7 ng/ml
(11 cycles)
P
(n = 34)
Total dose (IU) 788 (225-1650) 1087 (450-1650) 525 (225-900) <.001
Duration (days) 15 (6-30) 20 (12-30) 8 (6-14) <.001
Data are presented as median (range) and Mann Whitney test was used
for comparison.
Figure 3 Spearman correlations between baseline AMH and the dose and duration of hMG stimulation in 34 cycles.
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women with relatively high serum levels of AMH seem
to be resistant to all methods of ovarian stimulation.
Further studies are required to confirm this hypothesis
and to establish ways of overcoming this resistance. For
instance, studies could look into the benefit of adjust-
ment of the doses of CC or gonadotrophin according to
the level of circulating AMH.
Our findings seem to contradict the previous study by
Lie Fong and co-workers [9] who suggested that serum
AMH is not an accurate marker of ovarian response to
low dose gonadotrophin ovulation induction in patients
with PCOS. However, this assumption was not based on
a direct assessment of the predictive value of AMH, but
was based on the finding that AMH levels remained
stable during the gonadotrophin treatment cycle. It is
not clear how this conclusion was reached. Although,
circulating AMH remains constant during the treatment
cycle, which is consistent with our findings, it varies
considerably between different patients. Different serum
AMH levels may have different effects on follicular re-
sponse to gonadotrophin treatment.
Interestingly and in contrast to the above, high serum
AMH levels are known to predict over response to go-
nadotrophin ovarian stimulation in women without
PCOS [7,8]. However, the spectrum of circulating AMH
is different in women with and without PCOS. In otherFigure 4 Spearman correlations between baseline serum AMH levels
Ovarian volume in 20 women with PCOS undergoing hMG ovarian stwords, what is considered high AMH level in normal
women would be an average level in PCOS women. It is
therefore possible to hypothesise that there is an optimum
level of serum AMH, which is necessary for successful
ovarian stimulation. This level represents the overlap be-
tween women with and without PCOS. Levels above and
below the optimum AMH values are associated with poor
ovarian response to stimulation. This hypothesis requires
confirmation by further studies.
It should be noted that our cut-off AMH level applies
only to the AMH kit used in this study (Uscan assay). It
may, however, be possible to work out the equivalent
levels for other kits if the differences between these kits
are determined. We have previously reported that the
AMH values obtained by Uscan assay are approximately
50% of the values obtained by the IOT and Gen II assays,
which are more widely used in clinical practice [16].
Our findings in this study could help in counseling
women with PCOS regarding the chance of success and
the risks of over response with gonadotrophin therapy.
In addition, pre-treatment measurement of serum AMH
levels could help in determining the starting dose of
hMG. Patients with markedly raised AMH levels can be
given a high starting dose of gonadotrophin. However,
another study will be required to determine the starting
dose of hMG based on the serum level of AMH. In
addition to saving time and money, this approach mayand (A) serum Testosterone, (B) Free androgen index and (C)
imulation.
Table 5 gonadotrophins, androgens and ovarian volume in PCOS women with high vs. low baseline serum AMH
concentrations
AMH < 4.7 ng/ml (n = 8) AMH ≥ 4.7 ng/ml (n = 12) P
LH (IU/L) 8.2 (5.2-12.5) 10.0 (1.3-18.9) .33
FSH (IU/L) 4.7 (3.9-14.1) 4.5 (1.0-6.0) .67
Testosterone (nmol/l) 2.0 (1.6-2.5) 2.6 (0.9-3.6) .04
FAI 5.0 (3.0-7.0) 7.0 (2.0-13.0) .03
Ovarian volume (ml) 9.8 (8.0-13.5) 13.9 (8.5-16.7) .01
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month treatment before reaching the effective dose.
Strengths and limitations
The main strength of this study is its prospective design
with inclusion of consecutive patients fulfilling the study
inclusion criteria. The main limitation of this study is
the relatively small number of patients included. How-
ever, serum AMH levels are known to be generally stable
with minimal variation allowing small studies to show
significant differences. Furthermore, the findings in this
study are supported by multiple lines of statistical evi-
dence. We have used several statistical tests, which have
all consistently showed the same effect of circulating
AMH on ovarian response to hMG treatment. Another
limitation is the possible variation in study procedures
in the two centres involved. However, the procedures
were standardized in the two centres before starting the
study. One of the investigators (AM) was involved with
establishing the procedures in the two centres.
Conclusions
In conclusion, PCOS women with markedly elevated
serum AMH levels seem to be resistant to gonadotrophin
ovarian stimulation and may require higher doses of this
treatment. Pre-treatment measurement of serum AMH
concentrations may therefore be a valuable predictor of
success and may help in determining the starting dose.
We therefore recommend that all PCOS women requiring
gonadotrophin therapy would benefit from measuring
their baseline circulating AMH.
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